Menarini Group
Overview
The Opportunity
We are seeking a strategic and experienced Group R&D Controller (FP&A) to join our Corporate Finance Team and provide senior financial leadership for the Global R&D organization. This is a critical, hands‑on role responsible for driving the financial strategy, planning and stewardship for our complete R&D portfolio and for leading the financial planning, budgeting, forecasting, analysis and monthly business reporting for all R&D operations spanning both our high‑growth Oncology pipeline and our diverse non‑oncology therapeutic areas.
Reporting to the Global Head of Planning and Controlling, you will act as the primary financial co‑pilot to the Chief Medical Officer and other senior R&D leaders. You will be responsible for translating R&D's scientific and clinical strategy into a robust long‑range financial plan, ensuring optimal resource allocation and sound investment decisions across the portfolio.
You will be a key strategic partner to the R&D, Finance and Procurement teams. The successful candidate will deliver in‑depth monthly close analytics, coordinate the full budget and forecast cycles and help refine our approach to key stakeholder interactions, including monthly business reviews and presentations to Menarini Corporate.
This is a leadership role and you will manage a global controlling team, including 2 direct reports and other Local Controllers in a dotted‑line structure. You must be able to manage strategic‑level thinking while simultaneously executing the day‑to‑day responsibilities required to establish this function. Where your team members are responsible for "hands‑on" execution, your focus will be on designing the global framework, driving portfolio‑level strategy and delivering high‑impact analysis to the Menarini executive leadership team.
The ideal candidate is a highly motivated, collaborative team player with strong analytical and communication skills and meaningful experience supporting financial management in an evolving global biopharmaceutical organization.
Responsibilities Global R&D Financial Strategy & Leadership
Develop and own the global R&D financial strategy, ensuring alignment with both corporate finance objectives and scientific R&D goals.
Lead, mentor and develop the global R&D controlling team, fostering a culture of high performance and strong business partnership.
Act as the primary financial partner to the Chief Medical Officer and R&D leadership, providing strategic counsel on all financial matters.
Design, own and orchestrate the global R&D budgeting, forecasting and 5‑year planning processes, ensuring consistency and accuracy.
Portfolio & Investment Management
Provide comprehensive financial oversight and strategic analysis for the entire R&D portfolio, including both Oncology and Non‑Oncology programs.
Lead the financial evaluation of new R&D projects, including portfolio prioritization, resource allocation modeling and feasibility studies.
Develop and implement standardized methodologies for tracking and reporting on R&D project costs and investment returns across all stages of development.
Partner with R&D leaders to analyze and challenge portfolio assumptions, milestone timing and financial risk.
Controlling, Reporting, Financial Planning & Analysis (FP&A) & Business Partnership
Oversee the consolidation of all global R&D financials, ensuring qualified and timely monthly reporting and analysis for Head Office.
Present global R&D financial performance, forecasts and strategic insights to the executive leadership team.
Design and implement harmonized controlling processes, methodologies and financial systems across all global R&D sites to drive efficiency and comparability.
Establish and monitor key performance indicators (KPIs) for the global R&D organization.
Maintain ultimate oversight for global R&D cost management, budget control and headcount control.
Lead the accurate and timely preparation of the global R&D budget, forecasts and 5‑year strategic plan.
Maintain responsibility for the R&D project cost and investment budget, including detailed forecasting and tracking.
Conduct financial analysis of feasibility studies for new R&D projects to support strategic decision‑making.
Ensure qualified and timely monthly reporting and analysis of the business for both Head Office and local management.
Act as a primary financial partner to R&D, ensuring a strong local business linkage and close, day‑to‑day cooperation with HQ Business Controlling.
Analyze the business situation and market developments, providing insights and recommendations.
Provide special, ad‑hoc analysis as requested by local management or Head Office functions.
Oversee and manage local cost management and budget control for all R&D functions.
Manage headcount control versus budget, working in close cooperation with HR Controlling.
Take responsibility for controlling financial processes, identifying and implementing improvements.
Process Improvement
Lead the local implementation of new controlling processes and methodologies.
Train and support local staff in all Controlling‑related matters.
Lead and/or participate in special projects as assigned
Qualifications Required
Bachelor’s degree in Finance, Accounting, or a related field.
10-15+ years of progressive experience in financial planning and analysis, with a significant portion in a leadership role.
Deep experience in the biotechnology or pharmaceutical sector is required, with specific expertise in R&D and clinical trial finance.
Proven experience managing and developing a team; experience managing global or remote teams is highly preferred.
Exceptional strategic thinking, analytical and financial modeling skills, with the ability to translate complex data into actionable strategy and to communicate complex financial data clearly (both verbal and written).
Executive‑level communication and presentation skills; proven ability to influence and partner with senior leaders (e.g., C‑suite, R&D Heads).
Demonstrated experience with management reporting, financial analysis, budgeting and forecasting.
Strong understanding of financial systems and the design of global financial processes.
Mastery of Excel.
Excellent interpersonal skills; must be able to act with integrity and professionalism.
Ability to work well independently and without close supervision, keeping focused on objectives.
Proven ability to manage confidential and sensitive information.
Composure, positivity, flexibility and strong time management skills necessary to succeed in a performance‑driven environment under tight timelines.
Ability to distill a reasonable solution with limited information or unclear guidance.
Highly collaborative with the ability to navigate compexities amongst global finance and cross‑functional peers.
Hands‑on leader, capable of leading by example, with proven ability to build, develop and coach.
Strong work ethic to ensure financial and HR compliance.
Master’s degree or CPA.
Experience managing financials for both oncology and non‑oncology portfolios.
Experience implementing financial systems (e.g., SAP, NetSuite, Adaptive).
Other Requirements
25% travel requirement.
During first 3-6 months, travel may be as high as 50% (domestic/international)
Please note: this position is classified as a corporate office position. In accordance with the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.
Base Salary Range of $220,000-$270,000. Menarini Stemline offers generous compensation and benefits packages, including Short- and Long-Term Incentive Programs, Fidelity 401(k) (with company match), Anthem Premier PPO and HDHP insurance plans, Company‑paid Basic Life & AD&D insurance and pre‑tax FSA/HSA programs.
Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.
The Company
Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.
The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ‑listed biopharmaceutical company, the company marked its entry into the US oncology market.
Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.
Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical‑stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123‑targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).
Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first‑in‑class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.
Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late‑stage Phase 3 development for hormone receptor‑positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.
Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non‑invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.
Since 2021, MSB has offered in the US a menu of non‑invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US‑based Lab. The services include CMC enumeration, CTC enumeration and PDL‑1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.
In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first‑of‑its‑kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard‑of‑care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.
Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy‑based diagnostics for faster, more effective and precise patient management.
It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.
#J-18808-Ljbffr
We are seeking a strategic and experienced Group R&D Controller (FP&A) to join our Corporate Finance Team and provide senior financial leadership for the Global R&D organization. This is a critical, hands‑on role responsible for driving the financial strategy, planning and stewardship for our complete R&D portfolio and for leading the financial planning, budgeting, forecasting, analysis and monthly business reporting for all R&D operations spanning both our high‑growth Oncology pipeline and our diverse non‑oncology therapeutic areas.
Reporting to the Global Head of Planning and Controlling, you will act as the primary financial co‑pilot to the Chief Medical Officer and other senior R&D leaders. You will be responsible for translating R&D's scientific and clinical strategy into a robust long‑range financial plan, ensuring optimal resource allocation and sound investment decisions across the portfolio.
You will be a key strategic partner to the R&D, Finance and Procurement teams. The successful candidate will deliver in‑depth monthly close analytics, coordinate the full budget and forecast cycles and help refine our approach to key stakeholder interactions, including monthly business reviews and presentations to Menarini Corporate.
This is a leadership role and you will manage a global controlling team, including 2 direct reports and other Local Controllers in a dotted‑line structure. You must be able to manage strategic‑level thinking while simultaneously executing the day‑to‑day responsibilities required to establish this function. Where your team members are responsible for "hands‑on" execution, your focus will be on designing the global framework, driving portfolio‑level strategy and delivering high‑impact analysis to the Menarini executive leadership team.
The ideal candidate is a highly motivated, collaborative team player with strong analytical and communication skills and meaningful experience supporting financial management in an evolving global biopharmaceutical organization.
Responsibilities Global R&D Financial Strategy & Leadership
Develop and own the global R&D financial strategy, ensuring alignment with both corporate finance objectives and scientific R&D goals.
Lead, mentor and develop the global R&D controlling team, fostering a culture of high performance and strong business partnership.
Act as the primary financial partner to the Chief Medical Officer and R&D leadership, providing strategic counsel on all financial matters.
Design, own and orchestrate the global R&D budgeting, forecasting and 5‑year planning processes, ensuring consistency and accuracy.
Portfolio & Investment Management
Provide comprehensive financial oversight and strategic analysis for the entire R&D portfolio, including both Oncology and Non‑Oncology programs.
Lead the financial evaluation of new R&D projects, including portfolio prioritization, resource allocation modeling and feasibility studies.
Develop and implement standardized methodologies for tracking and reporting on R&D project costs and investment returns across all stages of development.
Partner with R&D leaders to analyze and challenge portfolio assumptions, milestone timing and financial risk.
Controlling, Reporting, Financial Planning & Analysis (FP&A) & Business Partnership
Oversee the consolidation of all global R&D financials, ensuring qualified and timely monthly reporting and analysis for Head Office.
Present global R&D financial performance, forecasts and strategic insights to the executive leadership team.
Design and implement harmonized controlling processes, methodologies and financial systems across all global R&D sites to drive efficiency and comparability.
Establish and monitor key performance indicators (KPIs) for the global R&D organization.
Maintain ultimate oversight for global R&D cost management, budget control and headcount control.
Lead the accurate and timely preparation of the global R&D budget, forecasts and 5‑year strategic plan.
Maintain responsibility for the R&D project cost and investment budget, including detailed forecasting and tracking.
Conduct financial analysis of feasibility studies for new R&D projects to support strategic decision‑making.
Ensure qualified and timely monthly reporting and analysis of the business for both Head Office and local management.
Act as a primary financial partner to R&D, ensuring a strong local business linkage and close, day‑to‑day cooperation with HQ Business Controlling.
Analyze the business situation and market developments, providing insights and recommendations.
Provide special, ad‑hoc analysis as requested by local management or Head Office functions.
Oversee and manage local cost management and budget control for all R&D functions.
Manage headcount control versus budget, working in close cooperation with HR Controlling.
Take responsibility for controlling financial processes, identifying and implementing improvements.
Process Improvement
Lead the local implementation of new controlling processes and methodologies.
Train and support local staff in all Controlling‑related matters.
Lead and/or participate in special projects as assigned
Qualifications Required
Bachelor’s degree in Finance, Accounting, or a related field.
10-15+ years of progressive experience in financial planning and analysis, with a significant portion in a leadership role.
Deep experience in the biotechnology or pharmaceutical sector is required, with specific expertise in R&D and clinical trial finance.
Proven experience managing and developing a team; experience managing global or remote teams is highly preferred.
Exceptional strategic thinking, analytical and financial modeling skills, with the ability to translate complex data into actionable strategy and to communicate complex financial data clearly (both verbal and written).
Executive‑level communication and presentation skills; proven ability to influence and partner with senior leaders (e.g., C‑suite, R&D Heads).
Demonstrated experience with management reporting, financial analysis, budgeting and forecasting.
Strong understanding of financial systems and the design of global financial processes.
Mastery of Excel.
Excellent interpersonal skills; must be able to act with integrity and professionalism.
Ability to work well independently and without close supervision, keeping focused on objectives.
Proven ability to manage confidential and sensitive information.
Composure, positivity, flexibility and strong time management skills necessary to succeed in a performance‑driven environment under tight timelines.
Ability to distill a reasonable solution with limited information or unclear guidance.
Highly collaborative with the ability to navigate compexities amongst global finance and cross‑functional peers.
Hands‑on leader, capable of leading by example, with proven ability to build, develop and coach.
Strong work ethic to ensure financial and HR compliance.
Master’s degree or CPA.
Experience managing financials for both oncology and non‑oncology portfolios.
Experience implementing financial systems (e.g., SAP, NetSuite, Adaptive).
Other Requirements
25% travel requirement.
During first 3-6 months, travel may be as high as 50% (domestic/international)
Please note: this position is classified as a corporate office position. In accordance with the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.
Base Salary Range of $220,000-$270,000. Menarini Stemline offers generous compensation and benefits packages, including Short- and Long-Term Incentive Programs, Fidelity 401(k) (with company match), Anthem Premier PPO and HDHP insurance plans, Company‑paid Basic Life & AD&D insurance and pre‑tax FSA/HSA programs.
Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.
The Company
Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.
The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ‑listed biopharmaceutical company, the company marked its entry into the US oncology market.
Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.
Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical‑stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123‑targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).
Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first‑in‑class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.
Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late‑stage Phase 3 development for hormone receptor‑positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.
Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non‑invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.
Since 2021, MSB has offered in the US a menu of non‑invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US‑based Lab. The services include CMC enumeration, CTC enumeration and PDL‑1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.
In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first‑of‑its‑kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard‑of‑care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.
Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy‑based diagnostics for faster, more effective and precise patient management.
It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.
#J-18808-Ljbffr